The FDA has approved new biosimilar medications for adult ADHD, including generic Strattera, Mydayis, and Cotempla XR-ODT. Accurate diagnosis and medical guidance are key to managing symptoms effectively across age groups.

Attention Deficit Hyperactivity Disorder (ADHD) affects brain development and daily life in individuals of all ages. While often identified in children, unmanaged symptoms can persist or worsen into adulthood. Recently, the FDA approved multiple biosimilar medications tailored for adult ADHD management, helping to alleviate severe symptoms in adults.

The Need for Accurate Diagnosis

Symptoms like difficulty concentrating, impulsivity, and hyperactivity in children may go unnoticed. A professional diagnosis is crucial to confirm ADHD and ensure appropriate treatment measures.

The FDA has authorized generic Strattera (atomoxetine) for both pediatric and adult ADHD patients.

This medication is available in different dosages; adherence to medical instructions is vital for safety.

Shire’s Mydayis (SHP465), approved for individuals aged 12 and above, combines amphetamine and dextroamphetamine to manage hyperactivity and impulsivity for up to 16 hours.

Cotempla XR-ODT, authorized for children aged 6 to 17, is the first orally disintegrating tablet that dissolves rapidly in the mouth, providing a convenient drug delivery method without water or chewing.

Since these medications work gradually, consulting a healthcare provider is essential to ensure safe and effective adult ADHD treatment.